We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company

Delisted

LJPC was delisted on the 19th of August, 2022.

71 hedge funds and large institutions have $382M invested in La Jolla Pharmaceutical Company in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

839% more call options, than puts

Call options by funds: $7.65M | Put options by funds: $815K

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

49% more capital invested

Capital invested by funds: $256M → $382M (+$126M)

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

3% less funds holding

Funds holding: 7371 (-2)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

Holders
71
Holders Change
-2
Holders Change %
-2.74%
% of All Funds
1.89%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.11%
New
8
Increased
25
Reduced
21
Closed
10
Calls
$7.65M
Puts
$815K
Net Calls
+$6.84M
Net Calls Change
+$4.49M
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
1
Tang Capital Management
California
$75.9M +$2.62M +139,035 +5%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$65.1M +$2.22M +117,775 +4%
BC
3
Broadfin Capital
New York
$34.4M +$3.12M +165,680 +13%
PA
4
Perceptive Advisors
New York
$31.5M -$179K -9,491 -0.7%
JHIU
5
Janus Henderson Investors US
Colorado
$29M -$490K -26,025 -2%
RI
6
RTW Investments
New York
$27.8M -$113K -5,995 -0.5%
Franklin Resources
7
Franklin Resources
California
$23M
Allianz Asset Management
8
Allianz Asset Management
Germany
$12.6M -$675K -35,842 -6%
Vanguard Group
9
Vanguard Group
Pennsylvania
$12M +$408K +21,642 +4%
BFA
10
BlackRock Fund Advisors
California
$9.22M +$495K +26,272 +7%
BIT
11
BlackRock Institutional Trust
California
$8.6M +$258K +13,689 +4%
Jennison Associates
12
Jennison Associates
New York
$6.13M +$99.3K +5,272 +2%
State Street
13
State Street
Massachusetts
$5.09M +$43K +2,280 +1%
PC
14
PointState Capital
New York
$4.76M +$3.77M +200,000 New
Northern Trust
15
Northern Trust
Illinois
$4.45M -$49.2K -2,611 -1%
Asset Management One
16
Asset Management One
Japan
$3.07M -$241K -12,767 -9%
SM
17
Sabby Management
Florida
$2.88M -$1.6M -85,167 -41%
Morgan Stanley
18
Morgan Stanley
New York
$2.86M -$348K -18,451 -13%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$2.36M +$54.9K +2,912 +3%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$1.63M +$18.1K +959 +1%
GIM
21
Granahan Investment Management
Massachusetts
$1.59M -$2.78M -147,354 -69%
BIM
22
BlackRock Investment Management
Delaware
$1.33M +$60.1K +3,189 +6%
AAM
23
Advisors Asset Management
Colorado
$1.04M -$52.6K -2,791 -6%
TAM
24
Tocqueville Asset Management
New York
$902K +$28.3K +1,500 +4%
Deutsche Bank
25
Deutsche Bank
Germany
$888K +$76.5K +4,062 +12%

LJPC Hedge Fund Activity: Q3 2016 in Review

71 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q3 2016, worth a combined $382M — up 49% from $256M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of LJPC and 8 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 25 added.

The largest buyer was PointState Capital, opening a new position worth an estimated $3.77M. The largest seller was Granahan Investment Management, cutting an estimated $2.78M.

  • 71 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q3 2016, down from 73 in Q2 2016.
  • Funds reported $382M of La Jolla Pharmaceutical Company stock for Q3 2016, up 49% quarter-over-quarter.
  • 8 funds opened new La Jolla Pharmaceutical Company positions in Q3 2016 and 10 closed out, a net change of -2 holders.
  • The largest La Jolla Pharmaceutical Company buyer in Q3 2016 was PointState Capital, an estimated $3.77M added.
  • The largest La Jolla Pharmaceutical Company seller in Q3 2016 was Granahan Investment Management, an estimated $2.78M sold.

Based on aggregated 13F filings for Q3 2016.